Immuron Limited is an Australian biopharmaceutical company that develops and commercializes orally delivered polyclonal antibodies derived from hyperimmune bovine colostrum to treat inflammatory and infectious diseases. The company markets Travelan®, an over-the-counter oral passive immunotherapy for travelers' diarrhea and gastrointestinal disorders sold in Australia, Canada, and the United States, along with Protectyn®, an immune health supplement for digestive and liver function. Its pipeline includes clinical-stage candidates IMM-124E for travelers' diarrhea and enterotoxigenic E. coli infections and IMM-529 for Clostridioides difficile infection, supported by partnerships with the U.S. Department of Defense; the company generates revenue through commercial product sales across pharmacy, online, and retail channels while advancing candidates through FDA biologics approval pathways.